May 8 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL UNVEILS PHASE 3 CLINICAL DATA OF FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER
* DAEWOONG PHARMA - FEXUPRAZAN SHOWED 99% OF MUCOSAL HEALING RATE AT WEEK 8 AND WAS WELL TOLERATED IN PATIENTS
* DAEWOONG PHARMA - FEXUPRAZAN ALSO SHOWED IMPROVED SYMPTOM RELIEF
* DAEWOONG PHARMA - ATYPICAL SYMPTOM SUCH AS COUGH WAS ALSO IMPROVED WITH TREATMENT OF FEXUPRAZAN
* DAEWOONG PHARMA - IN PATIENTS WITH MODERATE TO SEVERE SYMPTOMS, FEXUPRAZAN EXHIBITED SIGNIFICANTLY FASTER, BETTER HEARTBURN RELIEF VERSUS ESOMEPRAZOLE